We are live on ! Find out more

Royalty Pharma

RPRX

Market cap $26.4B

59.22 USD

+0.61

1.04%

At close Updated Sep 14, 10:42 AM EDT

1 day

1.04%

5 days

0.02%

1 month

1.06%

3 months

9.12%

6 months

28.46%

Year to date

52.39%

1 year

68.48%

5 years

49.28%

10 years

33.08%

About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Employees: 100

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 57.7%

Neutral 38.5%

Negative 3.8%

Royalty Pharma to present at upcoming investor conferences

NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:

Royalty Pharma to present at upcoming investor conferences

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history.

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen

NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an update on Novartis' Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied in patients with atherosclerotic cardiovascular (CV) disease and elevated lipoprotein(a), or Lp(a). The trial did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization in the overall study population, compared to placebo. Novartis intends to present the Lp(a) HORIZON trial data at an upcoming medical congress.

Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen

Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating

Royalty Pharma continues to deliver solid portfolio execution, supported by robust management and increased scalability for higher-value transactions. The company is capitalizing on inflows into the biopharma sector, with a strategic shift toward development-stage assets that yield higher IRRs and a strong track record of regulatory approvals. Several positive catalysts are coming up. All are poised to drive incremental royalty growth.

Royalty Pharma: Strong Execution, Higher Guidance, And Room For A Re-Rating

Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing

Royalty Pharma demonstrates high-quality, cash-generative compounding with durable royalty growth and disciplined capital deployment, supporting a buy rating. RPRX's 2Q26 results highlight 14% Royalty Receipts growth, elite 95% margins, and $728 million operating cash flow, reinforcing the core compounder thesis. Management raised 2026 Portfolio Receipts guidance to $3.4–$3.5 billion, projecting 7–10% royalty growth despite headwinds like Promacta erosion and IRA-related pressure.

Royalty Pharma: The Quiet Compounder The Market Is Still Mispricing

Zacks Investment Research

Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Royalty Pharma (RPRX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, RPRX crossed above the 20-day moving average, suggesting a short-term bullish trend.

Royalty Pharma (RPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder.

Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide.

Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide

Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma NASDAQ: RPRX raised its 2026 outlook for the second consecutive quarter after reporting higher second-quarter royalty receipts, continued capital deployment and progress across its development-stage pipeline.

Royalty Pharma Q2 Earnings Call Highlights

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

Royalty Pharma plc (RPRX) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™